RMD

$225.99-1.42 (-0.62%)

Market ClosedAs of Mar 20, 8:00 PM UTC

ResMed Inc.

Recent News

Simply Wall St.
Mar 22, 2026

ResMed (RMD) Valuation Check After Recent Share Price Pullback And Growth Expectations

ResMed stock performance and recent context ResMed (RMD) has drawn attention after recent trading, with shares last closing at US$225.99. The stock shows a 0.6% decline over the past day and softer returns over the week, month, and past 3 months. See our latest analysis for ResMed. Recent trading reflects fading short term momentum, with a 30 day share price return of a 12.8% decline and a year to date share price return of a 7.7% decline, while 1 year total shareholder return is 3.8%. If...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 19, 2026

After Plunging 12.0% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)

ResMed (RMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

ResMed (RMD) Upgraded to Buy: Here's What You Should Know

ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

Is Resmed Stock the Right Pick for Your Portfolio Now?

RMD expands mask and device sales while maintaining strong liquidity, but macro and competitive pressures loom.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 17, 2026

After Plunging 8.7% in 4 Weeks, Here's Why the Trend Might Reverse for ResMed (RMD)

The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.